"The Report Frontier
Pharma: Versatile Innovation in Immunology - Large Therapy Area
Pipeline with a High Degree of Repositioning Potential provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
Immunology
is a large therapy area characterized by disorders of the immune
system – specifically an aberrant immune response against healthy
tissues present in the body, leading to chronic or acute
inflammation. Depending on the specific site affected, this can lead
to various types of chronic pain and loss of mobility, and have a
negative impact on quality of life.
View Report @
http://www.marketresearchreports.biz/analysis/970728
This
disease area has a total of 2,145 products in active development,
trailing only oncology, infectious diseases and central nervous
system disorders in terms of pipeline size. There are a total of 529
immunology pipeline products that act on first-in-class molecular
targets, representing approximately 40% of the total immunology
pipeline for which the molecular target was disclosed.
Due
to a degree of crossover between immunology indications in terms of
their underlying pathophysiology, it is not uncommon for products
being developed for this therapy area to have developmental programs
testing them across multiple indications.
Approximately
one-fifth of first-in-class pipeline products are in development for
two or more indications within the therapy area. This presents an
opportunity for companies to develop innovative products across
multiple immune disorders, and therefore reach a larger pool of
patients than products developed for single indications.
Scope
- What are the key points of overlap in the pathophysiology of immune disorders?
- What is the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products?
- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- Do immunology products attract high deal values, and which specific product types are able to attract the highest values?
- Which molecule types and molecular targets dominate the deals landscape?
Reasons to buy
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
- Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the market.
- Review key pipeline trends by analyzing therapies by stage of development, molecule type and molecular target, and identify key trends regarding innovation within each segment.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the immunology pipeline have been assessed and ranked according to clinical potential, and the most promising early-stage targets have been further reviewed in greater detail.
- Identify promising first-in-class pipeline assets that have had no prior involvement in licensing or co-development deals, and are therefore potentially suitable for in-licensing
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Large Therapy Area
Characterized by a High Degree of Pathophysiological Crossover 5
2.2 Strong Pipeline Shows High
Level of Versatile Innovation 5
2.3 Substantial Deal Making
Activity Observed over the Past Decade 5
3 The Case for Innovation in the
Immunology Market 6
3.1 Growing Opportunities for
Biologic Products 7
3.2 Diversification of Molecular
Targets 7
3.3 Innovative First-in-Class
Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement
Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
4 Introduction 9
4.1 Therapy Area Introduction 9
4.2 Symptoms 9
4.3 Etiology and Pathophysiology 9
4.3.1 Innate Immunity 9
4.3.2 Adaptive Immunity 10
4.3.3 The Role of Cytokines 11
4.3.4 Autoimmunity 11
4.3.5 Etiologic Factors for
Autoimmunity and Allergies 12
4.3.6 Conclusion 12
4.4 Co-morbidities and
Complications 13
4.5 Epidemiology 13
4.6 Treatment 14
4.6.1 Non-Biologic
Disease-Modifying Anti-Rheumatic Drugs 15
4.6.2 Glucocorticoids 15
4.6.3 Biologics and Targeted
Therapies 15
5 Pipeline Landscape Assessment 17
5.1 Overview 17
5.2 Pipeline Development Landscape
18
5.3 Molecular Targets in the
Pipeline 19
5.4 Comparative Distribution of
Programs between the Oncology Market and Pipeline by Therapeutic
Target Family 20
5.5 First-in-Class and Versatile
Pipeline Programs 21
5.6 First-in-Class Immunology
Products by Phase, Molecule Type and Molecular Target 23
5.7 Versatility of First-in-Class
Pipeline Products 26
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment